<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545360</url>
  </required_header>
  <id_info>
    <org_study_id>BTL-703-001</org_study_id>
    <nct_id>NCT03545360</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the BTL-703 Treatment for the Non-invasive Lipolysis</brief_title>
  <official_title>Safety and Efficacy of the BTL-703 Treatment for the Non-invasive Lipolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTL Industries Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTL Industries Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate safety and efficacy of the BTL-703 device for the non-invasive
      lipolysis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Waist circumference reduction</measure>
    <time_frame>5 months</time_frame>
    <description>The waist circumference measure will be conducted in accordance to the WHO STEPwise approach to surveillance (2008.) and NHLBI Obesity Education Initiative (2000.) recommendations. The waist circumference after the therapy will be compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events following the treatment</measure>
    <time_frame>5 months</time_frame>
    <description>Occurrence of serious adverse events will be followed throughout the whole study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photo evaluation</measure>
    <time_frame>5 months</time_frame>
    <description>Correct identification of the pre- and post-treatment photos by blinded evaluators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>5 months</time_frame>
    <description>Subject Satisfaction Questionnaire will be given to subjects at every follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy discomfort</measure>
    <time_frame>2 months</time_frame>
    <description>Subject's discomfort (pain) level after each treatment will be assessed using the Discomfort Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated group of subjects, serves as its own control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BTL-703 (Treatment group)</intervention_name>
    <description>Treatment with BTL-703 device</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 22 years

          -  Voluntarily signed informed consent form

        Exclusion Criteria:

          -  Implanted electronic device such as a cardiac pacemaker, bladder stimulator, spinal
             cord stimulator or electrodes for a myoelectric prosthesis, etc.

          -  Diabetics dependent on insulin or oral hypoglycemic medications

          -  Known cardiovascular disease such as arrhythmias, congestive heart failure

          -  Cardiac surgeries such as cardiac bypass, heart transplant surgery, pacemakers.

          -  Prior surgical interventions for body sculpting of thighs or buttocks such as
             liposuction

          -  Medical, physical or other contraindications for body sculpting/ weight loss

          -  Current use of medication known to affect weight levels and/or cause bloating or
             swelling and for which abstinence during the course of study participation is not safe
             or medically prudent

          -  Any medical condition known to affect weight levels and/or to cause bloating or
             swelling

          -  Active infection, wound or other external trauma to the area to be treated

          -  Pregnant, breast feeding, or planning pregnant before the end of the study

          -  Serious mental health illness

          -  Active or recurrent cancer or current chemotherapy and/or radiation treatment

          -  Negative affection to heat
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Georgi Petkov</last_name>
    <phone>32 62 22 52</phone>
    <phone_ext>+359</phone_ext>
    <email>petkov@btlnet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aesthe Clinic</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radina Denkova, MD</last_name>
      <email>aestheclinic@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Radina Denkova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

